Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 9:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 199 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Mild-To-Moderate Alzheimer's Disease Clear all
Completed Phase 1 Interventional Results available

A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease

NCT03019536
View directory record Official record
Conditions
Alzheimer Disease
Interventions
LY3303560 - IV, Placebo - IV, Florbetapir F 18, Flortaucipir F18
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Melbourne, Florida • Orlando, Florida • Port Orange, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 4, 2026, 9:11 PM EDT
Completed Phase 1 Interventional Results available

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

NCT01193608
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AAB-003 (PF-05236812), Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 89 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
23
States / cities
Escondido, California • Hallandale, Florida • Ocala, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 4, 2026, 9:11 PM EDT
Completed Phase 1Phase 2 Interventional

Safety Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer's Disease

NCT00100334
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PPI-1019 (APAN)
Drug
Lead sponsor
PRAECIS Pharmaceuticals Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
San Juan Capistrano, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2006 · Synced Oct 4, 2026, 9:11 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease

NCT00359944
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AC-3933, Sugar Pill
Drug · Other
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
55 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
34
States / cities
LIttle Rock, Alaska • Phoenix, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Oct 4, 2026, 9:11 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

NCT04886063
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ATH-1017
Drug
Lead sponsor
LeonaBio
Industry
Eligibility
55 Years to 85 Years
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 4, 2026, 9:11 PM EDT
Completed Phase 2 Interventional

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

NCT01527916
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
placebo, donepezil, ABT-126
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
55 Years to 90 Years
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
8
States / cities
Delray Beach, Florida • Tampa, Florida • West Palm Beach, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Oct 4, 2026, 9:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study for Safety and Tolerability of AL002.

NCT03635047
View directory record Official record
Conditions
Healthy, Alzheimer Disease
Interventions
AL002, Saline Solution
Biological · Other
Lead sponsor
Alector Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
4
States / cities
Delray Beach, Florida • Orlando, Florida • The Villages, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 4, 2026, 9:11 PM EDT
Not listed Phase 2Phase 3 Interventional

Thalidomide for Patients With Mild to Moderate Alzheimer's Disease

NCT01094340
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Thalidomide
Drug
Lead sponsor
Banner Health
Other
Eligibility
50 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Sun City, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Oct 4, 2026, 9:11 PM EDT
Completed Phase 1 Interventional Results available

A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD

NCT02624778
View directory record Official record
Conditions
Alzheimer Disease
Interventions
LY3002813, Placebo
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Delray Beach, Florida • Orlando, Florida • The Villages, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 4, 2026, 9:11 PM EDT
Terminated Phase 3 Interventional Results available

Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers

NCT00490568
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rosiglitazone XR
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
51 Years to 91 Years
Enrollment
1,461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
41
States / cities
Litchfield Park, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 4, 2026, 9:11 PM EDT
Recruiting Phase 2 Interventional

Effect of Acetylcholinesterase Inhibitors on Bone Metabolism

NCT06041789
View directory record Official record
Conditions
Osteoporosis
Interventions
Donepezil, Memantine
Drug
Lead sponsor
Duke University
Other
Eligibility
50 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 4, 2026, 9:11 PM EDT
Terminated Phase 3 Interventional

Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease

NCT01969123
View directory record Official record
Conditions
Alzheimer's Disease, Dementia
Interventions
Drug: EVP-6124, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
55 Years to 85 Years
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
44
States / cities
Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 41 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 4, 2026, 9:11 PM EDT
Terminated Phase 3 Interventional

Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease

NCT01969136
View directory record Official record
Conditions
Alzheimer's Disease, Dementia
Interventions
Drug: EVP-6124, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
55 Years to 85 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
42
States / cities
Tucson, Arizona • Little Rock, Arkansas • Culver City, California + 39 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 4, 2026, 9:11 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

NCT01689246
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
TRx0237 150 mg/day, TRx0237 250 mg/day, Placebo
Drug
Lead sponsor
TauRx Therapeutics Ltd
Industry
Eligibility
Up to 89 Years
Enrollment
891 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
26
States / cities
Phoenix, Arizona • Laguna Hills, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 4, 2026, 9:11 PM EDT
Completed Phase 2 Interventional

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

NCT01549834
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ABT-126, placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
55 Years to 90 Years
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Fresno, California • Long Beach, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 4, 2026, 9:11 PM EDT
Not yet recruiting Not applicable Interventional

A Mobile Informatics Solution to Assist Caregivers in Care Coordination and Monitoring Social Engagement

NCT07773493
View directory record Official record
Conditions
Memory Disorders, Mild Cognitive Impairment, Dementia, Social Isolation, Caregiver Burden
Interventions
Social Reminder System
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 4, 2026, 9:11 PM EDT
Completed Phase 2Phase 3 Interventional Results available

ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

NCT04488419
View directory record Official record
Conditions
Alzheimer Disease, Dementia of Alzheimer Type
Interventions
ATH-1017, Placebo
Drug
Lead sponsor
LeonaBio
Industry
Eligibility
55 Years to 85 Years
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 4, 2026, 9:11 PM EDT
Terminated Phase 1 Interventional Results available

A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease

NCT01028911
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-03654746, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
55 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Oct 4, 2026, 9:11 PM EDT
Terminated Phase 3 Interventional Results available

Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

NCT05026177
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Simufilam, Placebo
Drug
Lead sponsor
Cassava Sciences, Inc.
Industry
Eligibility
50 Years to 87 Years
Enrollment
1,125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
65
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 4, 2026, 9:11 PM EDT
Completed Phase 2 Interventional

Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects

NCT04251182
View directory record Official record
Conditions
Alzheimer Disease
Interventions
15mg T3D-959, 30 mg T3D-959, 45 mg T3D-959, Placebos
Drug
Lead sponsor
T3D Therapeutics, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 4, 2026, 9:11 PM EDT
Completed Phase 1 Interventional Results available

SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.

NCT02036645
View directory record Official record
Conditions
Mild-Moderate Alzheimer's Disease, Healthy Elderly
Interventions
MEDI1814 for IV injection, MEDI1814 for Subcutaneous Injection, IV Placebo, Placebo for Subcutaneous Injection
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
55 Years to 85 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Glendale, California • Long Beach, California • Panorama City, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Oct 4, 2026, 9:11 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)

NCT02079909
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
T-817MA-H, T-817MA-L, Placebo
Drug
Lead sponsor
FUJIFILM Toyama Chemical Co., Ltd.
Industry
Eligibility
55 Years to 85 Years
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
50
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 4, 2026, 9:11 PM EDT
Completed Phase 2 Interventional Results available

Bexarotene Amyloid Treatment for Alzheimer's Disease

NCT01782742
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bexarotene, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
50 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Feb 12, 2016 · Synced Oct 4, 2026, 9:11 PM EDT
Completed Phase 2 Interventional Results available

A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab

NCT01723826
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Crenezumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
47
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Oct 4, 2026, 9:11 PM EDT